Ph.D. Paul A. Wagner - 01 Oct 2024 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Role
CEO, Secretary and Chair of the Board, Director
Signature
/s/ Paul A. Wagner, Ph.D.
Issuer symbol
FBRX
Transactions as of
01 Oct 2024
Net transactions value
-$506
Form type
4
Filing time
02 Oct 2024, 18:19:04 UTC
Previous filing
03 Jul 2024
Next filing
02 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FBRX Common Stock Options Exercise $0 +1,250 +1.6% $0.000000 77,568 01 Oct 2024 Direct F1, F2
transaction FBRX Common Stock Tax liability $506 -98 -0.13% $5.16 77,470 01 Oct 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FBRX Restricted Stock Units Options Exercise $0 -1,250 -10% $0.000000 11,250 01 Oct 2024 Common Stock 1,250 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
F2 The reported number of securities has been adjusted to reflect the Issuer's 1-for-25 reverse stock split effected on August 28, 2024.
F3 Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

Remarks:

CEO, Secretary and Chair of the Board